BRAF and metastatic melanoma: However, chemotherapy is still utilized in metastatic melanoma, mainly in patients lacking a targetable mutation in the BRAF/MEK signaling pathway, or developing secondary resistance to BRAF/MEK inhibitors, and/or in patients not suitable or refractory to immune checkpoint inhibition.